NASDAQ:OPGN OpGen (OPGN) Stock Price, News & Analysis → Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders) (Ad) Free OPGN Stock Alerts $2.50 +0.01 (+0.40%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.34▼$2.5250-Day Range$2.49▼$7.8052-Week Range$1.65▼$38.40Volume9,466 shsAverage Volume42,965 shsMarket Capitalization$3.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get OpGen alerts: Email Address Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About OpGen Stock (NASDAQ:OPGN)OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Read More OPGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPGN Stock News HeadlinesJune 5, 2024 | investorplace.comOPGN Stock Earnings: OpGen Meets Revenue for Q4 2023May 25, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 24, 2024 | globenewswire.comOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 16, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | globenewswire.comOpGen Announced 1-for-10 Reverse Stock SplitMay 4, 2024 | uk.finance.yahoo.comOpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo FinanceApril 30, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesApril 29, 2024 | globenewswire.comOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 27, 2024 | investing.comOpGen CEO David Lazar buys additional shares worth $150kApril 26, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 23, 2024 | globenewswire.comOpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 22, 2024 | finance.yahoo.comOpGen, Inc. (OPGN)March 28, 2024 | msn.comShares Rip In Reaction To Activist Investor Becoming CEOMarch 27, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.08%March 26, 2024 | markets.businessinsider.comDow Gains 100 Points; McCormick Posts Upbeat ResultsMarch 26, 2024 | markets.businessinsider.comNasdaq Gains Over 50 Points; US Durable Goods Orders Rise In FebruaryMarch 26, 2024 | msn.comCrude Oil Moves Lower; TD SYNNEX Earnings Top EstimatesMarch 26, 2024 | msn.comWhy Is Penny Stock OpGen Trading Higher On Tuesday?March 26, 2024 | marketwatch.comOpGen Investor David Lazar Is Named CEOMarch 25, 2024 | globenewswire.comOpGen Announces Acquisition of Preferred Stock by David LazarMarch 20, 2024 | money.usnews.comOpgen IncFebruary 9, 2024 | msn.comOpGen Inc Reports Unregistered Equity Sales UpdateFebruary 9, 2024 | msn.comOpGen Inc. Extends Warrant Exercise Deadline to 2024December 17, 2023 | morningstar.comOpGen Inc OPGNDecember 13, 2023 | bizjournals.comRockville biotech OpGen fights to retain Nasdaq listing as business teetersSee More Headlines Receive OPGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today6/15/2024Next Earnings (Estimated)6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:OPGN CUSIPN/A CIK1293818 Webwww.opgen.com Phone(240) 813-1260Fax301-869-9684Employees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($65.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,670,000.00 Net Margins-955.79% Pretax Margin-955.79% Return on Equity-1,827.76% Return on Assets-189.49% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$3.42 million Price / Sales0.98 Cash FlowN/A Price / Cash FlowN/A Book Value($11.55) per share Price / Book-0.22Miscellaneous Outstanding Shares1,340,000Free Float755,000Market Cap$3.35 million OptionableNot Optionable Beta-0.65 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Oliver Schacht Ph.D. (Age 53)Executive VP of Corporate Development Comp: $408kMr. David Elliot Lazar (Age 33)CEO & Chairman Key CompetitorsPsychemedicsNASDAQ:PMDDermTechNASDAQ:DMTKBioNexus Gene LabNASDAQ:BGLCFresh2 GroupNASDAQ:FRESAclarionNASDAQ:ACONView All CompetitorsInstitutional OwnershipChase Investment Counsel CorpBought 331,890 shares on 5/2/2024Ownership: 2.630%View All Institutional Transactions OPGN Stock Analysis - Frequently Asked Questions Should I buy or sell OpGen stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares. View OPGN analyst ratings or view top-rated stocks. How have OPGN shares performed in 2024? OpGen's stock was trading at $4.20 on January 1st, 2024. Since then, OPGN shares have decreased by 40.5% and is now trading at $2.50. View the best growth stocks for 2024 here. Are investors shorting OpGen? OpGen saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 37,200 shares, an increase of 376.9% from the May 15th total of 7,800 shares. Based on an average trading volume of 175,400 shares, the short-interest ratio is presently 0.2 days. Currently, 2.9% of the company's shares are sold short. View OpGen's Short Interest. When is OpGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 17th 2024. View our OPGN earnings forecast. How were OpGen's earnings last quarter? OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, August, 10th. The medical research company reported ($9.30) EPS for the quarter, missing analysts' consensus estimates of ($7.10) by $2.20. The medical research company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.90 million. OpGen had a negative trailing twelve-month return on equity of 1,827.76% and a negative net margin of 955.79%. During the same quarter in the previous year, the firm posted ($26.00) earnings per share. When did OpGen's stock split? Shares of OpGen reverse split on Monday, May 20th 2024. The 1-10 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did OpGen IPO? OpGen (OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager. Who are OpGen's major shareholders? OpGen's stock is owned by a number of institutional and retail investors. Top institutional investors include Chase Investment Counsel Corp (2.63%). Insiders that own company stock include Johannes Bacher and Oliver Schacht. View institutional ownership trends. How do I buy shares of OpGen? Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPGN) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.